Related Experiment Videos
Osteoporosis in mixed connective tissue disease
E Bodolay1, P Bettembuk, A Balogh
1University of Debrecen, Medical and Health Science Center, 4004 Debrecen, Móricz Zs. 22, Hungary. bodolai@iiibel.dote.hu
Clinical Rheumatology
|September 25, 2003
Summary
Postmenopausal women with mixed connective tissue disease (MCTD) have an increased risk of osteoporosis, particularly in the lumbar spine. Factors like disease duration and corticosteroid use contribute to bone loss.
Area of Science:
- Rheumatology
- Endocrinology
- Osteoporosis Research
Background:
- Mixed Connective Tissue Disease (MCTD) is an autoimmune disorder with overlapping features of systemic lupus erythematosus, scleroderma, and polymyositis.
- Osteoporosis is a significant health concern in postmenopausal women, characterized by low bone mass and increased fracture risk.
Purpose of the Study:
- To investigate the prevalence of osteoporosis in postmenopausal women diagnosed with MCTD.
- To identify potential contributing factors to bone loss in this patient population.
Main Methods:
- Dual-energy X-ray absorptiometry (DXA) was used to assess bone mineral density (BMD) in the lumbar spine and femoral neck of 58 postmenopausal women with MCTD.
- Serum levels of osteocalcin and sex hormones (estradiol, testosterone, dehydroepiandrosterone sulfate) were measured.
- Patients' medical history, including corticosteroid use and disease duration, was reviewed.
Main Results:
- 25.8% of MCTD patients exhibited osteoporosis (T score < -2.5) in the lumbar spine.
- No significant difference in femoral neck BMD was observed between MCTD patients and age-matched controls.
- Low BMD was present in patients on and off corticosteroids, with bone loss correlating with disease duration and corticosteroid therapy.
- MCTD patients showed lower serum osteocalcin and sex hormone levels compared to controls.
Conclusions:
- MCTD is associated with an increased risk of bone loss, particularly in the lumbar spine.
- Potential contributing factors include the autoimmune disease itself, corticosteroid treatment, impaired osteoblast function, and reduced serum sex hormone levels.